MedPath

Ketorolac

Generic Name
Ketorolac
Brand Names
Acular, Acuvail, Omidria, Readysharp Anesthetics Plus Ketorolac, Sprix, Toradol, Toronova Suik
Drug Type
Small Molecule
Chemical Formula
C15H13NO3
CAS Number
74103-06-3
Unique Ingredient Identifier
YZI5105V0L
Background

Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution.

It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis. Impressively, ketorolac has a similar efficacy to standard doses of morphine and meperidine making it a useful opioid sparing agent.

Indication

Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and has antipyretic, analgesic and anti-inflammatory properties. It is indicated for short term management of acute pain that requires the calibre of pain management offered by opioids. Clinicians may choose to initiate ketorolac to manage post-operative pain, spinal and soft tissue pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders and headaches among other ailments. Regardless of the etiology of pain, patients should use the lowest possible dose, and avoid using ketorolac for an extended period of time (ideally ≤ 5 days). A benefit of choosing ketorolac over other analgesics with similar potency is that that there does not appear to be a risk of dependence or tolerance with ketorolac use.

Associated Conditions
Acute Migraine, Eye Pain, Inflammation, Macular Edema, Cystoid, Ocular Itching, Pericarditis Acute, Pseudophakic Cystoid Macular Oedema, Severe Acute Pain, Acute, moderate Pain, Chronic aphakic cystoid macular edema, Intraoperative miosis, Postoperative ocular pain

Therapeutic Variables in Cataract Surgery

Phase 4
Completed
Conditions
Cataract Surgery
First Posted Date
2006-12-04
Last Posted Date
2007-08-21
Lead Sponsor
Innovative Medical
Registration Number
NCT00407017
Locations
🇺🇸

The Center for Excellence in Eye Care, Miami, Florida, United States

Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo

Phase 3
Completed
Conditions
Cataracts
Interventions
First Posted Date
2006-11-30
Last Posted Date
2016-11-18
Lead Sponsor
Alcon Research
Target Recruit Count
227
Registration Number
NCT00405730
Locations
🇫🇷

Bordeaux, Bordeaux, France

A Comparison of Bupivacaine and Ketorolac for Postoperative Analgesia After Iliac Crest Bone Harvesting

Phase 3
Completed
Conditions
Postoperative Pain
Interventions
First Posted Date
2006-11-30
Last Posted Date
2013-08-20
Lead Sponsor
The Hospital for Sick Children
Target Recruit Count
54
Registration Number
NCT00405262
Locations
🇨🇦

The Hospital for Sick Children, Toronto, Ontario, Canada

Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%

Phase 4
Completed
Conditions
Vitrectomy
First Posted Date
2006-09-18
Last Posted Date
2008-09-25
Lead Sponsor
Innovative Medical
Registration Number
NCT00377546
Locations
🇺🇸

Ophthalmic Consultants of Boston, Boston, Massachusetts, United States

Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation

Phase 4
Completed
Conditions
Cataract Extraction
First Posted Date
2006-08-21
Last Posted Date
2018-06-14
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
40
Registration Number
NCT00366691
Locations
🇺🇸

Storm Eye Institute, Medical University of South Carolina, Charleston, South Carolina, United States

Intrathecal Ketorolac in Patients With Intrathecal Morphine Dose Escalation

Phase 2
Withdrawn
Conditions
Pain
First Posted Date
2006-07-07
Last Posted Date
2017-11-06
Lead Sponsor
Wake Forest University Health Sciences
Registration Number
NCT00349401

Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients

Phase 4
Completed
Conditions
Cataract
First Posted Date
2006-07-04
Last Posted Date
2007-07-13
Lead Sponsor
Innovative Medical
Registration Number
NCT00347503
Locations
🇺🇸

Bucci Laser Vision, Wilkes Barre, Pennsylvania, United States

Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK

Phase 4
Completed
Conditions
Myopia
Hyperopia
First Posted Date
2006-07-04
Last Posted Date
2006-07-04
Lead Sponsor
Center For Excellence In Eye Care
Target Recruit Count
40
Registration Number
NCT00347204

Effect of Prophylactic Ketorolac on CME After Cataract Surgery

Not Applicable
Completed
Conditions
Macular Edema, Cystoid
First Posted Date
2006-06-09
Last Posted Date
2016-01-13
Lead Sponsor
Queen's University
Target Recruit Count
98
Registration Number
NCT00335439
Locations
🇨🇦

Hotel Dieu Hospital, Kingston, Ontario, Canada

Nevanac 3-Month Safety Study With QID Dosing

Phase 3
Completed
Conditions
Cataract
Interventions
First Posted Date
2006-06-02
Last Posted Date
2012-03-05
Lead Sponsor
Alcon Research
Target Recruit Count
149
Registration Number
NCT00332774
Locations
🇺🇸

Contact Alcon for Trial Locations, Fort Worth, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath